AIMS/HYPOTHESIS: Oxidative stress is involved in the pathogenesis of diabetic nephropathy. The antioxidant enzyme catalase plays a key role in redox regulation in the kidney. We investigated associations of catalase gene (CAT) polymorphisms and plasma catalase activity with diabetic nephropathy in type 1 diabetic patients. METHODS: We genotyped nine single nucleotide polymorphisms (SNPs) in the CAT region in participants from the Survival Genetic Nephropathy (SURGENE) (340 French participants, 10 year follow-up) and the Génétique de la Néphropathie Diabétique (GENEDIAB) (444 Belgian and French participants, 8 year follow-up) study cohorts. Replication was performed in a Brazilian cross-sectional cohort (n = 451). Baseline plasma catalase activity was measured in SURGENE (n = 120) and GENEDIAB (n = 391) participants. RESULTS: The A allele of rs7947841 was associated with the prevalence of incipient (OR 2.79, 95% CI 1.21, 6.24, p = 0.01) and established or advanced nephropathy (OR 5.72, 95% CI 1.62, 22.03, p = 0.007), and with the incidence of renal events, which were defined as new cases of microalbuminuria or progression to a more severe stage of nephropathy during follow-up (HR 1.82, 95% CI 1.13, 2.81, p = 0.01) in SURGENE participants. The same risk allele was associated with incipient nephropathy (OR 3.13, 95% CI 1.42, 7.24, p = 0.004) and with the incidence of end-stage renal disease (ESRD) (HR 2.11, 95% CI 1.23, 3.60, p = 0.008) in GENEDIAB participants. In both cohorts, the risk allele was associated with lower catalase activity. Associations with incipient and established or advanced nephropathy were confirmed in the replication cohort. CONCLUSIONS/ INTERPRETATION: CAT variants were associated with the prevalence and incidence of diabetic nephropathy and ESRD in type 1 diabetic patients. Our results confirm the protective role of catalase against oxidative stress in the kidney.
AIMS/HYPOTHESIS: Oxidative stress is involved in the pathogenesis of diabetic nephropathy. The antioxidant enzyme catalase plays a key role in redox regulation in the kidney. We investigated associations of catalase gene (CAT) polymorphisms and plasma catalase activity with diabetic nephropathy in type 1 diabeticpatients. METHODS: We genotyped nine single nucleotide polymorphisms (SNPs) in the CAT region in participants from the Survival Genetic Nephropathy (SURGENE) (340 French participants, 10 year follow-up) and the Génétique de la Néphropathie Diabétique (GENEDIAB) (444 Belgian and French participants, 8 year follow-up) study cohorts. Replication was performed in a Brazilian cross-sectional cohort (n = 451). Baseline plasma catalase activity was measured in SURGENE (n = 120) and GENEDIAB (n = 391) participants. RESULTS: The A allele of rs7947841 was associated with the prevalence of incipient (OR 2.79, 95% CI 1.21, 6.24, p = 0.01) and established or advanced nephropathy (OR 5.72, 95% CI 1.62, 22.03, p = 0.007), and with the incidence of renal events, which were defined as new cases of microalbuminuria or progression to a more severe stage of nephropathy during follow-up (HR 1.82, 95% CI 1.13, 2.81, p = 0.01) in SURGENE participants. The same risk allele was associated with incipient nephropathy (OR 3.13, 95% CI 1.42, 7.24, p = 0.004) and with the incidence of end-stage renal disease (ESRD) (HR 2.11, 95% CI 1.23, 3.60, p = 0.008) in GENEDIAB participants. In both cohorts, the risk allele was associated with lower catalase activity. Associations with incipient and established or advanced nephropathy were confirmed in the replication cohort. CONCLUSIONS/ INTERPRETATION:CAT variants were associated with the prevalence and incidence of diabetic nephropathy and ESRD in type 1 diabeticpatients. Our results confirm the protective role of catalase against oxidative stress in the kidney.
Authors: Nicolas Godin; Fang Liu; Garnet J Lau; Marie-Luise Brezniceanu; Isabelle Chénier; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan Journal: Kidney Int Date: 2010-03-17 Impact factor: 10.612
Authors: Amanda Crawford; Robert G Fassett; Jeff S Coombes; Dale A Kunde; Kiran D K Ahuja; Iain K Robertson; Madeleine J Ball; Dominic P Geraghty Journal: Nephrol Dial Transplant Date: 2011-02-16 Impact factor: 5.992
Authors: M Marre; X Jeunemaitre; Y Gallois; M Rodier; G Chatellier; C Sert; L Dusselier; Z Kahal; L Chaillous; S Halimi; A Muller; H Sackmann; B Bauduceau; F Bled; P Passa; F Alhenc-Gelas Journal: J Clin Invest Date: 1997-04-01 Impact factor: 14.808
Authors: Marie-Luise Brezniceanu; Fang Liu; Chih-Chang Wei; Isabelle Chénier; Nicolas Godin; Shao-Ling Zhang; Janos G Filep; Julie R Ingelfinger; John S D Chan Journal: Diabetes Date: 2007-10-31 Impact factor: 9.461
Authors: M-L Brezniceanu; F Liu; C-C Wei; S Tran; S Sachetelli; S-L Zhang; D-F Guo; J G Filep; J R Ingelfinger; J S D Chan Journal: Kidney Int Date: 2007-03-07 Impact factor: 10.612
Authors: Suzana M Vieira; Maria B Monteiro; Tatiana Marques; Ana M Luna; Maria A Fortes; Márcia Nery; Márcia Queiroz; Sérgio A Dib; Márcio F Vendramini; Mirela J Azevedo; Luis H Canani; Maria C Parisi; Elizabeth J Pavin; Daniel Giannella-Neto; Maria L Corrêa-Giannella Journal: BMC Med Genet Date: 2011-09-30 Impact factor: 2.103
Authors: Vanessa Sodré de Souza; Gabriela Corassa Rodrigues da Cunha; Beatriz R Versiani; Claudiner Pereira de Oliveira; Maria Teresa Alves Silva Rosa; Silviene F de Oliveira; Patricia N Moretti; Juliana F Mazzeu; Aline Pic-Taylor Journal: Mol Syndromol Date: 2022-02-11